Anti-™9SF3 monoclonal antibody
Pre-made anti-™9SF3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to ™9SF3/™9SF3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1929-Ab-1/ GM-Tg-hg-IP1929-Ab-2 | Anti-Human ™9SF3 monoclonal antibody | Human |
GM-Tg-rg-IP1929-Ab-1/ GM-Tg-rg-IP1929-Ab-2 | Anti-Rat ™9SF3 monoclonal antibody | Rat |
GM-Tg-mg-IP1929-Ab-1/ GM-Tg-mg-IP1929-Ab-2 | Anti-Mouse ™9SF3 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1929-Ab-1/ GM-Tg-cynog-IP1929-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ™9SF3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1929-Ab-1/ GM-Tg-felg-IP1929-Ab-2 | Anti-Feline ™9SF3 monoclonal antibody | Feline |
GM-Tg-cang-IP1929-Ab-1/ GM-Tg-cang-IP1929-Ab-2 | Anti-Canine ™9SF3 monoclonal antibody | Canine |
GM-Tg-bovg-IP1929-Ab-1/ GM-Tg-bovg-IP1929-Ab-2 | Anti-Bovine ™9SF3 monoclonal antibody | Bovine |
GM-Tg-equg-IP1929-Ab-1/ GM-Tg-equg-IP1929-Ab-2 | Anti-Equine ™9SF3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1929-Ab-1/ GM-Tg-hg-IP1929-Ab-2; GM-Tg-rg-IP1929-Ab-1/ GM-Tg-rg-IP1929-Ab-2; GM-Tg-mg-IP1929-Ab-1/ GM-Tg-mg-IP1929-Ab-2; GM-Tg-cynog-IP1929-Ab-1/ GM-Tg-cynog-IP1929-Ab-2; GM-Tg-felg-IP1929-Ab-1/ GM-Tg-felg-IP1929-Ab-2; GM-Tg-cang-IP1929-Ab-1/ GM-Tg-cang-IP1929-Ab-2; GM-Tg-bovg-IP1929-Ab-1/ GM-Tg-bovg-IP1929-Ab-2; GM-Tg-equg-IP1929-Ab-1/ GM-Tg-equg-IP1929-Ab-2 |
Products Name | Anti-™9SF3 monoclonal antibody |
Format | mab |
Target Name | ™9SF3 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-™9SF3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1929-Ag-1 | Recombinant multi-species ™9S3/ ™9SF3/ EP70-P-iso protein |
ORF Viral Vector | pGMLPm004053 | mouse Tm9sf3 Lentivirus plasmid |
ORF Viral Vector | vGMLPm004053 | mouse Tm9sf3 Lentivirus particle |
Target information
Target ID | GM-IP1929 |
Target Name | ™9SF3 |
Gene ID | 56889,107358,309475,704905,612786,101097763,614147,100070803 |
Gene Symbol and Synonyms | 1810073M23Rik,2810031D16Rik,EP70-P-iso,mKIAA4036,RGD1564625,SMBP,™9SF3 |
Uniprot Accession | Q9HD45 |
Uniprot Entry Name | ™9S3_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000077147 |
Target Classification | N/A |
The target: ™9SF3, gene name: ™9SF3, also named as EP70-P-iso, SMBP. Predicted to be involved in protein localization to membrane. Predicted to be located in exocytic vesicle. Predicted to be active in membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.